Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Professor; Intramural Faculty, Koch Institute

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Paul Thompson



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Jaeger, AM, Stopfer, LE, Ahn, R, Sanders, EA, Sandel, DA, Freed-Pastor, WA, Rideout, WM 3rd, Naranjo, S, Fessenden, T, Nguyen, KB et al.. 2022. Nature , .
    doi: 10.1038/s41586-022-04839-2PMID:35705813
  2. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Wang, C, Cui, A, Bukenya, M, Aung, A, Pradhan, D, Whittaker, CA, Agarwal, Y, Thomas, A, Liang, S, Amlashi, P et al.. 2021. Cell Rep 37, 110021.
    doi: 10.1016/j.celrep.2021.110021PMID:34818534
  3. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Duong, E, Fessenden, TB, Lutz, E, Dinter, T, Yim, L, Blatt, S, Bhutkar, A, Wittrup, KD, Spranger, S. 2022. Immunity 55, 308-323.e9.
    doi: 10.1016/j.immuni.2021.10.020PMID:34800368
  4. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Horton, BL, Morgan, DM, Momin, N, Zagorulya, M, Torres-Mejia, E, Bhandarkar, V, Wittrup, KD, Love, JC, Spranger, S. 2021. Sci Immunol 6, eabi8800.
    doi: 10.1126/sciimmunol.abi8800PMID:34714687
  5. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. Bao, R, Spranger, S, Hernandez, K, Zha, Y, Pytel, P, Luke, JJ, Gajewski, TF, Volchenboum, SL, Cohn, SL, Desai, AV et al.. 2021. J Immunother Cancer 9, .
    doi: 10.1136/jitc-2021-002417PMID:34272305
  6. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo, A, Li, Z, Gui, DY, Sullivan, LB, Zagorulya, M, Do, BT, Ferreira, R, Naamati, A, Ali, A, Lewis, CA et al.. 2021. Mol Cell 81, 691-707.e6.
    doi: 10.1016/j.molcel.2020.12.012PMID:33382985
  7. Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas. Dongre, A, Rashidian, M, Eaton, EN, Reinhardt, F, Thiru, P, Zagorulya, M, Nepal, S, Banaz, T, Martner, A, Spranger, S et al.. 2021. Cancer Discov 11, 1286-1305.
    doi: 10.1158/2159-8290.CD-20-0603PMID:33328216
  8. Frontiers in cancer immunotherapy-a symposium report. Cable, J, Greenbaum, B, Pe'er, D, Bollard, CM, Bruni, S, Griffin, ME, Allison, JP, Wu, CJ, Subudhi, SK, Mardis, ER et al.. 2021. Ann N Y Acad Sci 1489, 30-47.
    doi: 10.1111/nyas.14526PMID:33184911
  9. Impact of anatomic site on antigen-presenting cells in cancer. Zagorulya, M, Duong, E, Spranger, S. 2020. J Immunother Cancer 8, .
    doi: 10.1136/jitc-2020-001204PMID:33020244
  10. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Ascierto, PA, Fox, BA, Urba, WJ, Anderson, AC, Atkins, MB, Borden, EC, Brahmer, JR, Butterfield, LH, Cesano, A, Chen, DC et al.. 2020. J Immunother Cancer 8, .
    doi: 10.1136/jitc-2020-000878PMID:32300051
More Publications



Photo credit: Kelsey Montgomery